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1. Bi-Level Graph Neural Networks
We introduce BI-GNN (Bi-Level Graph Neural Networks)
for modeling biological link prediction tasks such as drug-
drug interaction (DDI) (Vilar et al., 2012) and protein-
protein interaction (PPI) (Keskin et al., 2008). Taking drug-
drug interaction as an example, existing methods using ma-
chine learning either only utilize the link structure between
drugs without using the graph representation of each drug
molecule (Zitnik et al., 2018; Ma et al., 2018), or only lever-
age the individual drug compound structures without using
graph structure for the higher-level DDI graph (Deac et al.,
2019). Readers are referred to a recent survey (Sun et al.,
2019) for more details.
We demonstrate our model using the drug-drug interaction
prediction task as an example. Drug-drug interactions occur
when the presence of one drug changes the effect of another
drug producing an observed side effect (Wishart et al., 2018).
Specifically, we consider the transductive setting of drug
repurposing (Pushpakom et al., 2019), in which predicting
interactions between existing drugs along with leveraging
interaction data can help infer similar physiological effects
for other existing drugs (Zhou et al., 2015). This is espe-
cially important with the recent COVID-19 pandemic, as
drug repurposing techniques aim to find existing drugs that
may be helpful in treading COVID-19 (Hamilton, 2020).
Our framework is also extendable to other biological link
prediction tasks with different interacting biological entities,
e.g. proteins (Fout et al., 2017; Huan et al., 2005).
The key idea is to fundamentally view the data as a bi-level
graph, in which the highest level is a representing the inter-
action between biological entities (interaction graph), and
each biological entity itself is further expanded to its intrin-
sic graph representation (representation graphs), in which
the graph is either flat like a drug compound (Kearnes et al.,
2016) or hierarchical like a protein with amino acid level
graph, secondary structure, tertiary structure, etc (Wikipedia
contributors, 2020). Our BI-GNN not only allows the usage
of information from both the high-level interaction graph
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Figure 1. A bi-level graph view of the drug-drug interaction data,
in which the number of levels is 2. Existing GNN methods operate
only on either the representation graphs or the single interaction
graph without utilizing both under the GNN framework. Node
colors in the representation graphs denote molecular level element
types. Edge colors in the interaction graph denote drug interactions
types.
and the low-level representation graphs, but also offers a
baseline for future research opportunities to address the
bi-level nature biological interaction networks.
Definitions We denote an undirected, unweighted graph
G = (V, E) with N = |V| nodes. In addition, we let Gh =
(Vh, Eh) denote the higher level interaction network with
node set Vh and edge set Eh. Moreover each ehi ∈ Eh
can be of different types. Let R denote the set of all edge
types. Each vi ∈ Vh is also a graph which we denote as
Gli = (V li , E li). The set of all graphs in the lower level is
{Gl1,Gl2, ...,Gl|Vh|}. Fig 1 shows an example with |Vh| = 7.
Node features for the ith representation graph are summa-
rized in a Ni ×Dl matrix Hli where Ni = |Vi|. Likewise
node features for the interaction graph are denoted by a
N ×Dh matrix Hh. Taking DDI as an example in which
the representation graphs are molecular structures of drugs,
H li would represent atom features such as the atomic num-
ber, whether an atom is aromatic, its hybridization, the
number of hydrogen atoms attached to the atom etc. of Gli .
Currently, we do not consider edge features in the lower
level graph but this can be easily extended in future work.
BI-GNN BI-GNN consists of the following sequential
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Table 1. Comparison of baseline methods. GATl runs on the representation graphs while GATh runs on the interaction graph
Method Low-Level Model High-Level Model Feature of Drugs
FP-PRED N/A N/A Molecular Structure
LL-GNN GATl × 5 N/A Molecular Structure
MHCADDI (Deac et al., 2019) {GAT-GMN}l × 3 N/A Molecular Structure
DECAGON-R (Zitnik et al., 2018) N/A GATh × 3 Random
DECAGON-FP (Zitnik et al., 2018) N/A GATh × 3 Molecular Structure
DECAGON-OH (Zitnik et al., 2018) N/A GATh × 3 Learned Transductively
BI-GNN (this paper) GATl × 5 GATh × 3 Molecular Structure
stages: 1) Lower Level Representation Graph Neural Net-
work generates vector representations for each representa-
tion graph; 2) Higher Level Interaction Graph Neural Net-
work further propagates information from the lower level
graph embeddings to neighboring nodes in the interaction
graph, which provides the final graph representations to
a fully connected network to obtain a final link prediction
score. In this scenario, the representation graph may contain
more than one level, one at the amino acid level and another
at the secondary structure level.
1.1. Stage I: Lower Level Representation Graph
Embedding
In Stage I, we generate the representation graphs’ graph
embeddings. In general this can be obtained through any
graph embeddinging method. For example, one can use
node embedding models such as Graph Convolutional Net-
works (Kipf & Welling, 2017), Graph Attention Networks
(Velikovi et al., 2018), or Graph Isomorphism Networks
(Xu et al., 2019) followed by a READOUT function, a
function that takes the embeddings of nodes as input and
outputs a single embedding for the graph. Additionally, one
can use hierarchical graph representation models such as
DIFFPOOL (Ying et al., 2018) or GRAPH-U-NET (Gao &
Ji, 2019).
In this work, we use Graph Attention Networks (GAT) with
multi-scale READOUT of the updated node embeddings.
Formally, the k-th layer of GAT is defined as:
x
(k+1)
i = ReLU(αi,ixˆi
(k) +
∑
j∈N (i)
αi,jxˆj
(k)) (1)
αi,j =
exp(LeakyReLU(a(k)
T
[xˆi
(k)||xˆj (k)]))∑
m∈N (i) exp(LeakyReLU(a(k)
T
[xˆi
(k)||xˆm(k)]))
.
(2)
Here, xˆi is the transformed node embedding from initial
feature:
xˆi =Wxi. (3)
N (i) is the set of all first-order neighbors of node i plus
node i itself; W (l) ∈ RDl×Dl+1 is the weight matrix as-
sociated with the n-th GAT layer; αi,j is a scalar attention
weight that node i gives to node j; a(l) ∈ R2Dl is the atten-
tion weight vector; and || is vector concatenation.
Multi-Scale READOUT Inspired by GIN (Xu et al.,
2019), we concatenate the node representations across all
layers of the GAT. This allows the model to consider all
structural information, at various levels of granularity. For
K GAT layers the representation graph embeddings xG can
be expressed as:
xG = CONCAT(READOUT(x
(k)
v |v ∈ G)|k = 1, 2, ...K).
(4)
1.2. Stage II: Higher Level Interaction Node
Embedding
Graph embeddings from Stage I as initial node features
Hh ∈ RN×Dh for the interaction graph. This is motivated
by the intuition that the lower level network presents a useful
initial representation from which the higher level network
further enhances for the task. Similar to Stage I, many
different node embedding methods may be used to refine the
entity representation. We continue to use a different set of
GAT layers for the higher level node embedding. Because
only the final node representation in the interaction graph is
needed, there is no multi-scale READOUT. Additionally,
in the case of multiple edge types, the GAT propagation
becomes
x
(t+1)
i = ReLU(
∑
r∈R
(αri,ixˆi
r(t) +
∑
j∈N r(i)
αri,jxˆj
r(t)))
(5)
whereN r(i) is the set of neighbors of node i that have edge
type r; xˆri =Wrx
r
i ; and α
r
i,j is calculated as in Equation 2
but parameterized by ar.
For link prediction, we concatenate the representations of a
pair of entities after T upper level GAT layers and feed it
into fully connected layers to predict a link prediction score:
pred(vi, vj) = MLP(xi||xj). (6)
We choose this decoder over simpler alternatives such as
dot product between drug embeddings, because empirically
we find this yields better performance.
For multiclass link prediction (multiple edge types), the
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fully connected layers output C scores for C classes. We
use cross entropy loss with logits for the loss function.
2. Experiments
We train BI-GNN on two DDI datasets, DRUGBANK
(Marinka Zitnik & Leskovec, 2018; Wishart et al., 2018)
and DRUGCOMBO (Liu et al., 2020) whose details can be
found in the supplementary material.
2.1. Baseline Methods
To fairly compare the uses of different levels of information
we aim to use similar architectures as BI-GNN, summarized
in Table 1 and detailed in the supplementary material.
Representation Graph Models For models that only use
the lower level representation graph we focus on three vari-
ants. The first which we call FP-PRED, feeds extended
connectivity fingerprint (ECFP) (Rogers & Hahn, 2010)
representations directly into the prediction layers. ECFPs
are representations of chemical structures which capture
relevant molecular features and molecular structure. The
second is LL-GNN which is the lower level model out-
lined in section 1.1. The last model is MHCADDI (Deac
et al., 2019) which uses intra-graph message passing and
inter-graph co-attention. We implement a similar model that
uses Graph Matching Networks (GMN) (Li et al., 2019) for
inter-graph attention.
Interaction Graph Models
Under models that only use the interaction graph, we con-
sider DECAGON (Zitnik et al., 2018), which considers
protein-protein networks and protein-drug networks on top
of the DDI as the input graph. We adopt DECAGON for the
DDI network only. More specifically, we focus on three
different initializations of Hh ∈ RN×Dh , the input drug
features: (1) one hot initialization which we call DECAGON-
OH, (2) random initialization denoted as DECAGON-R, and
(3) ECFP (Rogers & Hahn, 2010) initialization which we
refer to as DECAGON-FP.
Table 2. Overall link prediction accuracy of all the methods on two
datasets. Top two results are highlighted in bold.
Method DRUGBANK DRUGCOMBOROC PR ROC F1
FP-PRED 0.630 0.647 0.648 0.495
LL-GNN 0.822 0.800 0.813 0.661
MHCADDI 0.864 0.844 0.824 0.681
DECAGON-R 0.898 0.896 0.853 0.753
DECAGON-FP 0.905 0.903 0.844 0.731
DECAGON-OH 0.940 0.939 0.864 0.748
BI-GNN 0.933 0.929 0.859 0.767
Figure 2. The distribution of node degrees across different training
data ratios (percentage of DDI pairs in the training set denoted as
“TR”).
2.2. Results
From Table 2 we observe the effectiveness of different levels
of network information. For models that use only the lower
level representation graphs, inter-graph communication pro-
vides better performance (LL-GNN vs MHCADDI) and
utilizing GNNs allow better learning of the graph represen-
tations suit the link prediction task (LL-GNN vs FP-PRED).
However, DECAGON baselines, which only use the higher
level interaction network, significantly outperform the lower
level models. Finally, utilizing both levels of information
with BI-GNN is better than DECAGON-FP and DECAGON-
R and is competitive with DECAGON-OH. Nevertheless, it
must be noted that despite the strong performance by one
hot initialization, it is not scalable to larger interaction net-
works. Specifically, because Dh grows linearly with the
number of the nodes, the weight matrix becomes larger. In
addition, as described in section 2.3 one hot initialization
is unable to generalize representations for unseen nodes or
nodes which have few neighbors.
2.3. When BI-GNN Performs the Best
Since the overall performance shows that BI-GNN is either
the best or the second best, we conduct additional evaluation
to investigate under what circumstances BI-GNN performs
better than all the baseline methods. Specifically, we conjec-
ture that the high performance achieved by DECAGON-OH
is due to its ability to learn drug representations in a transduc-
tive way. From Equation 3, if the initial feature is one-hot,
after multiplying with the learnable weight matrix W , each
drug is essentially represented as a randomly initialized but
learnable embedding. On one hand, this inherently prohibits
the using of DECAGON-OH to inductive setting where a
drug in the testing set can be unseen during training whose
embedding is then unknown. On the other hand, however,
this also allows DECAGON-OH to take advantage of the
transductive nature of the drug re-purposing task and often
achieve the best performance.
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(a) TR=0.1 (b) TR=0.3 (c) TR=0.5 (d) TR=0.7
Figure 3. Performance of all methods on DRUGBANK under different training data ratios. Under each case, further breakdown of
performance under different node degree splits (Figure 2) are shown.
(a) LL-GNN (b) LL-GNN
(c) DECAGON-OH (d) DECAGON-OH
(e) BI-GNN (f) BI-GNN
Figure 4. Left: Drug embeddings generated by different models
with color indicating clustering. Right: The DRUGBANK interac-
tion graph with node colors corresponding to the clustering and
cirle size indicating node degree.
What if the link structure is not available or very sparse?
To DECAGON-OH, sparse neighborhood would limit its
learning ability to adjust each drug representation, and lower
performance would be expected. In contrast, our BI-GNN
may still leverage the inherent molecular structure of each
drug compound. Based on this hypothesis, we split the
drugs into “bins” based on node degrees. Figure 2 shows
the distribution of number of nodes in different bins, where
bins with lower indices correspond to sparse regions of the
DDI network. We then evaluate the performance of each
model under each bin. As shown in Figure 3, BI-GNN
indeed outperforms DECAGON-OH when node degree is
low. In practice, drugs may come with different amount of
known interacting drugs, and our framework is especially
good for drugs with little to no information available.
2.4. Correlation between Drug Embeddings and
Drug-Drug Interactions
To gain a better understanding of what kind of represen-
tations are useful for the link prediction task, we per-
form the following visualization procedure. For LL-GNN,
DECAGON-OH, and BI-GNN, we take the final drug em-
beddings before the final prediction layer, and project them
into a 2D plane using t-SNE (Maaten & Hinton, 2008). We
then use DBSCAN (Ester et al., 1996) to cluster the embed-
dings and color the drug nodes in the interaction network
according to the clustering assignment, resulting in Figure 4.
It is clear that DECAGON-OH and BI-GNN learn useful
drug embeddings which highly correlate to the link struc-
ture in the DDI graph, while the embeddings generated by
LL-GNN which only relies on the molecular structure do
not lead to good performance for link prediction in the in-
teraction graph. Based on Section 2.3 and 2.4, we conclude
that the message passing across the higher level graph con-
tributes the most to the performance of GNN models on the
DDI prediction task.
3. Conclusion and Future Work
We propose a multi-level GNN framework for biological
entity link prediction by constructing a bi-level graph with
higher level representing the interaction graph between bi-
ological entities while the lower levels representing the in-
dividual biological entity such as drug, protein, etc. In the
future, we plan to extend our method to the protein-protein
interaction task where each protein is represented as a hi-
erarchical graph with amino acids, secondary structures,
etc. Additionally, to improve the accuracy of our BI-GNN,
we will explore the integration of graph matching and the
introduction of additional input features into our framework.
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A. Dataset Description
We run experiments on 2 real word datasets on drug-drug
interaction. Moreover, for each drug, we obtain its SMILE
string from which we can derive the molecular structure. We
one hot encode the lower level representation graph’s node
features. These include the atomic number, the number of
attached hydrogen atoms, the hybridization, whether it is an
acceptor or donor and whether it is aromatic.
A.1. DRUGBANK
DRUGBANK is a dataset of drug-drug interactions from
the DRUGBANK database containing detailed drug data
and its interaction information1. We take the pairs mined
by (Marinka Zitnik & Leskovec, 2018) and keep the pairs
given as DRUGBANK Ids from which we can find the drugs’
molecular structure information. After preprocessing, there
are 1309 drug representation graphs and 41072 drug inter-
actions. For training and evaluation we perform negative
sampling on the positive drug pairs.
A.2. DRUGCOMBO
DRUGCOMBO is a database containing drug-drug combi-
nations obtained from various sources including external
databases, manual curations, and experimental results2. We
take the pairs of drug combinations that have been classified
1https://www.drugbank.ca/
2http://drugcombdb.denglab.org/main
as exhibiting synergistic or antagonistic effects. We cross-
reference PubChem3, a database of chemical molecules for
the molecular structures. Similar to before, we keep the
pairs in which molecular structure information is found.
In total, there are 3242 drug representation graphs, 34335
drug pairs classified as having synergistic effects, and 15057
pairs classified as having antongonistic effects. We also
treat the different classes as edge features in the interaction
graph and use it in our higher level propagation. Similar to
DRUGBANK we perform negative sampling for each known
effect.
B. Parameter Settings
For each lower level and higher level GAT we have hidden
dimensions of 64. The input dimensions for DECAGON-
FP and DECAGON-R are 64 dimensions while the input
dimension for DECAGON-OH is the number of drugs in
the DDI. We use 3 higher level GAT layers for DECAGON
models. For LL-GNN we use 5 lower level GAT layers
while for MHCADDI we use 3 blocks of GAT followed
by GMN co-attention. Experiments are ran on an Intel i7-
6800K CPU and Nvidia Titan GPU. We split the dataset
intro training validation and testing sets based on the known
pairs. For training, for all models except MHCADDI, we
have a batch size of 64 graphs and select all adjacent pairs
in the training set. For MHCADDI, we have a batch size
of 128 pairs as each graph is dependent on its paired graph
only for its own representation. Additionally, we use the
Adam optimizer (Kingma & Ba, 2015) with the learning
rate set to 0.001 and the the number of iterations set to
10000. We use the mean aggregator as our READOUT
function. We evaluate on the validation set after every 100
iterations and employ early stopping if performance does not
improve over a window size of 15. Finally, all experiments
were implemented with the PyTorch and PyTorch Geometric
libraries (Fey & Lenssen, 2019).
C. Baseline Details and Related Work
C.1. MHCADDI vs GMN
In this work, we mention the use of inter-graph attention in
MHCADDI with GMNs (Li et al., 2019). For two graphs
Gl1, Gl2 and node xi ∈ Gl1 the model as described in (Deac
et al., 2019) computes the inter-graph representation as
x
(k+1)
i,inter =
∑
j∈Gl2
α
(k+1)
i,j W
(k+1)
1 x
(k)
j (7)
3https://pubchem.ncbi.nlm.nih.gov/
Bi-Level Graph Neural Networks for Drug-Drug Interaction Prediction
α
(k+1)
i,j =
exp(〈W (k+1)2 x(k)i ,W (k+1)2 x(k)j 〉)∑
j′∈Gl2 exp(〈W
(k+1)
2 x
(k)
i ,W
(k+1)
2 x
(k)
j′
〉)
.
(8)
Here, 〈·, ·〉 is the dot product. In our model, we utilize a
similar attention mechanism adopted from Graph Matching
Networks (Li et al., 2019). Specifically we compute the
inter-graph message as follows
x
(k+1)
i,inter =
∑
j∈Gl2
αi,j(x
(k)
i − x(k)j ) (9)
ai,j =
exp(cos(x
(k)
i ,x
(k)
j ))∑
j∈Gl2 exp(cos(x
(k)
i ,x
(k)
j ))
. (10)
In both cases, MHCADDI and GMN update the next step
node representation, x(k+1)i , using a combination of the
representation from intra-graph message passing and inter-
graph message passing.
C.2. DECAGON vs BI-GNN
In the main text, we compare with three versions of
DECAGON (Zitnik et al., 2018), but here we would like
to point out that the original work of DECAGON uses ad-
ditional input features for the drugs as well as a heteroge-
neous interaction network including both drugs and proteins,
whereas our three versions use the same amount of input
features as BI-GNN for fair comparison. In addition, drug-
drug similarity has also been explored for DDI prediction
in literature (Ma et al., 2018). In future, we plan to incor-
porate these additional information to further improve the
prediction accuracy.
